Skip to main content
. 2020 Oct 24;3(1):vdaa145. doi: 10.1093/noajnl/vdaa145

Table 1.

Summary of Targeted Therapies for Gliomas in Completed or Currently Enrolling Clinical Trials

Target Drug Clinical Trial
BRAF Vemurafenib NCT01524978
RAS/RAF/MEK/ERK TAK-580 NCT03429803
Dabrafenib/Trametinib NCT02034110, NCT02684058
Encorafenib/Binimetinib NCT03973918
EGFR ABT-414 NCT01800695
H3 K27M Panobinostat NCT02717455
IDH1/2 Vorasidenib (AG-881) NCT04164901
VEGF(R) Bevacizumab NCT00345163
Regorafenib NCT03970447